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Abstract
Background: We describe the first case of systemic cat scratch disease in a patient receiving
peginterferon α-2a and ribavirin for treatment of hepatitis C. Cases of adult systemic CSD are
extremely infrequent and immunomodulatory treatment for hepatitis C has been associated with
aberrant host responses to common pathogens.
Case presentation: A 52 year old man being treated for hepatitis C presented with diffuse
lymphadenopathy, weight loss, fevers and splenic lesions. Symptoms were initially confused with
adverse effects of his regimen, delaying recognition of his infection. Diagnostic investigation,
including histopathology, microbiology and serologic parameters, confirmed that his illness was due
to disseminated cat scratch disease with Bartonella henselae.
Conclusion: Disseminated CSD is exceptionally rare in adults. We describe the first case of
disseminated cat scratch disease associated with peginterferon α and ribavirin to alert clinicians of
the need to be aware of unusual manifestations of common infections in this population.
Background
Cat scratch disease (CSD) most commonly presents as a
localized granulomatous and suppurative lymphadenop-
athy caused by Bartonella henselae, a small fastidious gram-
negative argyrophillic bacillus [1,2]. While the over-
whelming majority of systemic CSD occurs in children,
especially with hepatosplenic involvement, disseminated
CSD is exceedingly rare in immunocompetent adults
[3,4].
Interferon α and ribavirin are mainstays of treatment for
chronic hepatitis C, that have been associated with aber-
rant immune-mediated host responses, that may resemble
adverse pharmacologic effects. In this report, we present
the first description of disseminated CSD in an adult
receiving interferon  2a and ribavirin for treatment of
chronic hepatitis C, in whom signs and symptoms were
initially confused with adverse effects of medications. We
offer our experience to alert clinicians of the need for
awareness of unusual manifestations of commons infec-
tions in this population.
Case Presentation
A 52-year-old male with a history of hepatitis C, genotype
1b, was nearing completion of a one-year course of treat-
ment with pegylated interferon  2a (180 ug subcutane-
ously each week) and ribavirin (1200 mg orally each day).
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His initial hepatitis C viral RNA had declined from 2.2 ×
106 IU/ml at onset of treatment, to <65 IU/ml by six
months, and remained undetectable thereafter. Toward
the end of his course of treatment, he developed fatigue,
malaise, drenching night sweats, intermittent fever and
chills. On the last visit for hepatitis C treatment, axillary
and cervical lymphadenopathy was noticed. His symp-
toms were initially attributed to adverse effects of inter-
feron  α, prompting premature discontinuation of
treatment after 10.5 months. One month after onset of
symptoms, he presented to a nearby hospital for further
workup.
He was transferred to the Buffalo VA Western New York
Healthcare System with complaints of malaise and left
sided mid back pain. He had a documented weight loss of
40 lbs over the previous year. He appeared chronically ill
and fatigued. He had a temperature of 101°F and a heart
rate of 105 beats per minute. Generalized lymphadenop-
athy was noted, including cervical, axillary, inguinal and
right epitrochlear lymph nodes. The nodes were 1–2 cm
wide, firm, movable and nontender. He had left sided
abdominal fullness and mild tenderness, but no guarding
or rebound. The remainder of his examination was non-
contributory.
CBC revealed hemoglobin of 11.7 g/dl (13.5–17), white
blood cell count of 7.6 K/cmm (4.4–10.7), platelet count
of 511 K/cmm (140–375) and ESR of 80 mm/hr. Serum
chemistries included a sodium of 130 mEq/L (135–145),
creatinine of 0.9 mg/dl (0.7–1.4). SGOT was 68 units/l
(12–34), SGPT: 95 units/l (25–65). A serum ELISA for
human immunodeficiency virus was negative. Rheuma-
toid and anti-nuclear antibody titers were also negative.
Computerized tomography (CT) scan of chest and abdo-
men revealed mild lymphadenopathy and multiple con-
trast enhancing hypodense lesions in the spleen (Figure
1).
Initial clinical suspicion included lymphoma and he
underwent a lymph node biopsy. Further history revealed
exposure to numerous cats. He frequented a neighbor
who had 6–9 cats, including kittens, with which the
patient had played, and from whom he received numer-
ous scratches. Serologic studies were sent for antibodies to
Bartonella, Chlamydia, Toxoplasma and Brucella. He was
given ibuprofen for symptomatic relief.
A biopsy of an epitrochlear lymph node displayed necro-
tizing granulomata with peripheral palisading epithelioid
cells, with an admixture of plasma cells and lymphocytes.
Areas of stellate necrosis with microabscesses were evi-
dent, consistent with cat scratch disease (Figure 2). Stains
for acid-fast bacilli and fungi showed no organisms.
Lymph node biopsy material was cultured for routine
pathogens, acid-fast bacilli and fungal organisms.
Although the Gram stain displayed abundant white blood
cells, all cultures were sterile.
Over the next 3–4 days, the patient defervesced and
improved symptomatically on ibuprofen alone. By the
eighth day, serum antibody titers (IgG and IgM) for Bar-
tonella henselae were reported as >1:16,384. He continued
to improve without further treatment. Six months later he
was doing well and had regained 25 lbs of weight. An
abdominal CT scan revealed complete resolution of
splenic lesions.
Conclusion
This is the first reported case of systemic CSD with gener-
alized lymphadenopathy and splenic involvement in an
adult associated with immunomodulatory treatment for
hepatitis C. In our patient, the diagnosis of CSD was
established by: 1) history of exposure to cats, 2) obtaining
sterile pus from a lymph node with no growth on routine
cultures, 3) lymph node biopsy displaying classic findings
of necrotizing stellate granulomata with microabscesses,
and 4) an extremely high titer serum antibody response to
B. henselae.
Cross sectional cut of CT scan of abdomen at the time of  clinical presentation Figure 1
Cross sectional cut of CT scan of abdomen at the time of 
clinical presentation. Multiple hypoechoic densities are 
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Cat scratch disease was first described in 1950 [5],
although manifestations that constitute the disease have
been known for over 100 years. Typically lesions may
appear at the site of a cat scratch, often from a young kit-
ten, as a papule, pustule or vesicle, followed by fever,
regional lymphadenopathy and occasional systemic
symptoms. Illness is usually self-limited, resolving in 2–3
months with no treatment. Atypical signs and symptoms
occur most often in children and include Parinaud's ocu-
loglandular syndrome (conjunctivitis, conjunctival granu-
lomata with preauricular lymphadenopathy),
encephalitis, myelitis, hepatosplenic disease and dissemi-
nation [6,7]. Rarely, splenic CSD may require splenec-
tomy [8,9]. The clinical resemblance to lymphoma, of
splenic abscesses in disseminated CSD such as our patient
presented with, has been described [10].
Laboratory diagnosis of CSD includes appropriate histo-
logical findings and detection of serum antibodies to B.
henselae by enzyme immunoassay, which has a specificity
of up to 95% and sensitivity of 83–95%, when IgM titer is
greater than 1:250 [11,12]. PCR assay of tissue or blood,
although not employed routinely, may have high sensitiv-
ity and specificity [13]. PCR techniques have been applied
to immunofluorescent detection of B. henselae in tissue
sections. Although sensitivity of this method has been var-
iable, high specificity of positive samples may be of value
when the diagnosis is in question [14,15]. Recent reports
of high sensitivity of immunohistochemistry with mono-
clonal antibodies to B. henselae, tested on a limited num-
bers of tissue samples, suggest potential future value [16].
Although well characterized, these techniques are not uni-
versally employed [17].
While the specific factors that permit dissemination of
CSD are not known, clinical experience confirms that the
host response to B. henselae contributes to the manifesta-
tion of disease. This is illustrated by the experience with B.
henselae in AIDS patients, where the same pathogen that
causes self-limited regional lymphadenopathy in immu-
nocompetent hosts, causes bacillary angiomatosis and
peliosis hepatis [18]. However, other immunodeficient
states, such as chronic lymphocytic leukemia and T cell
lymphoma, can also trigger dissemination of CSD
[19,20]. In fact, the immunomodulatory effects of co-
infection with EBV may have been responsible for one
case of disseminated CSD [21].
Although the impact of interferon α and ribavirin on host
immune response has had limited characterization, aber-
rant host responses associated with this regimen are well
known, including immune-mediated Graves' disease and
sarcoidosis [22]. Although advanced forms of infection,
including visceral leishmaniasis [23] have been reported
with interferon-α and ribavirin therapy, a major focus of
infectious complications has been associated with drug
induced neutropenia [24]. This was clearly not the case in
our patient. Interferon α exerts biological activities by
binding to cell membranes receptors, initiating numerous
cellular events, including upregulation of Th1 cells and
modulation of immunological activities of macrophages
and lymphocytes [25]. While the precise clinical relevance
of these events is not known, it is difficult to ignore the
temporal relationship between administration of this reg-
imen and onset of disease in our patient, most likely due
to immunomodulatory factors, aside from neutropenia,
affected by this regimen. In addition, adverse effects of
therapy, including flu-like symptoms, fatigue (47–64%),
fever (39–46%), and rigors (35%), were also present at
the onset of our patient's illness, resulting in delayed rec-
ognition of his infection [26].
The success and increasing utilization of interferon α and
ribavirin for treatment of hepatitis C will undoubtedly
reveal a greater number of interferon-related side effects in
the future. We offer the experience of our patient to alert
clinicians of the need to be aware of aberrant presenta-
tions of infections in this population.
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Hematoxylin and eosin stain of lymph node biopsy showing a  stellate granuloma and microabscesses Figure 2
Hematoxylin and eosin stain of lymph node biopsy showing a 
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